

SstI Polymorphism of the Apolipoprotein CIII Gene in Iranian Hyperlipidemic Patients: A Study in Semnan Province

*¹Ahmad Reza Bandegi, ²Mohsen Firoozrai, ³Mohammad Reza Akbari Eidgahi,
^{4,5}Parviz Kokhaei

Abstract

Objective(s)

The Sst-I polymorphic site on the 3' untranslated region of the apo CIII gene, has been previously reported to be associated with hypertriglyceridemia. The aim of the present study was to explore the association between Sst-I polymorphism with plasma lipid and lipoprotein levels in hyperlipidemic (HLP) patients from Semnan province, Iran.

Materials and Methods

Genomic DNA was prepared from 76 patients with HLP and 75 matched healthy subjects. DNA samples were amplified by polymerase chain reaction. The samples were analyzed by restriction fragment length polymorphism (RFLP) method using SstI enzyme.

Results

The genotype and allelic frequencies for this polymorphism were significantly different between HLP and normolipidemic groups ($P < 0.002$). Plasma triglyceride (TG) level was higher in both groups, in S2S2 genotype was more than in the S1S1 and S1S2 genotypes, however, there was no significant difference in comparison with the control group. Subjects with S1S2 + S2S2 genotypes in compare to S1S1 genotype had odd ratio of 2.8 (95% CI: 1.41-5.56, $P < 0.003$) for developing hypertriglyceridemia.

Conclusion

The results showed that the presence of rare S2 allele was associated with change in TG level in the selected population.

Keywords: Apolipoprotein C-III, Genetic, Hyperlipidemia, Iran, PCR, Polymorphism

1- Department of Biochemistry, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran

*Corresponding author: Tel: +98-231-3354171; Fax: +98-231-3354161; email: arbandegi@yahoo.ca

2- Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

3- Biotechnology Research Center, Semnan University of Medical Sciences, Semnan, Iran

4- Immune and Gene Therapy Lab, CCK, Karolinska University Hospital Solna, Stockholm, Sweden

5- Department of Immunology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran

Introduction

Apolipoprotein CIII (apo CIII), glycoprotein composed of 79 amino acids, is synthesized mainly in the liver (1). In fasting normolipidemic subjects, apo CIII is present on high density lipoproteins (HDL) and triglyceride-rich lipoproteins (TRLs) (2). The *in vivo* function of apo CIII is not clearly described. A number of studies proposed its involvement in the regulation of TRLs catabolism (3, 4). *In vitro* studies have demonstrated that apo CIII reduces the catabolism of TRLs by inhibiting lipoprotein lipase (LPL). This enzyme plays a central role in hydrolyzing triglyceride (TG) transported in TRLs (5). Overexpression of human apo CIII gene in transgenic mice resulted in hypertriglyceridemia (6). Apo CIII has direct atherogenic effect on vascular cells (7).

The apo CIII gene is located on the long arm of chromosome 11q23-q24 where it is flanked by the Apo AI and Apo AIV gene; these genes are randomly organized in a cluster of ~17-kb DNA (1). The apo CIII gene contains four exons (8) and is ~ 3.1 kb (3). The expression of apo CIII gene is controlled by positive and negative regulatory elements, which are extended throughout the gene cluster (9).

Several polymorphisms in the apo CIII gene have been detected that associate with variation in plasma lipid concentrations (10-12). One of these genetic variants is SstI polymorphism in the 3' untranslated region (3' UTR) of exon 4 in the Apo CIII gene (13, 14). This transversion from C to G at nucleotide 3238 results in a loss of the recognition sequence for the restriction enzyme SstI. This substitution produces two alleles: S1 and S2. Multiple studies have suggested a close association between rare S2 allele and elevated levels of plasma TG (15-17) and apo CIII concentration (18, 19). Other studies, however, have found no association between the polymorphism and hypertriglyceridemia (20-22).

In view of the importance of apo CIII gene as a marker for hypertriglyceridemia, the present study investigated possible association between SstI polymorphism and plasma lipid levels in 151 individuals from Semnan province, Iran; given the high incidence of dyslipidemia in the Iranian adults (23).

Materials and Methods

Study population

A total of 76 unrelated Iranian subjects (33 males and 43 females) with primary hyperlipidemia were recruited from the Fatemeh Hospital (Semnan, Iran). Subjects with a triglyceride (TG) concentration ≥ 200 mg/dl and Total cholesterol (TC) ≥ 240 mg/dl were included in hyperlipidemic (HLP) group. Patients with secondary hyperlipidemia, hypothyroidism, diabetes mellitus, hypertension, alcoholism, renal failure and hepatic disease as well as patients receiving drugs affecting lipid profile were excluded. Furthermore, 75 age - and sex matched (35 males and 40 females) healthy controls were selected to participate in the study. The healthy control was defined as normal healthy group with plasma concentration of TG <200 mg/dl and TC < 240 mg/dl, and as the one who did not smoke or use lipid - lowering drugs. These subjects were randomly selected by health screening at the same hospital. Both patients and controls had Iranian origin and exhibited a homogenous genetic background. Body mass index (BMI) was defined as weight/height² (kg/m²). The study was approved by the local Ethics Committee at Iran University of Medical Sciences and written informed consent was obtained from all subjects participating in the study.

Plasma lipids and apolipoproteins analysis

Venous blood samples (10 ml) were obtained from the subjects after an overnight fasting. Total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-c), and low density lipoprotein-cholesterol (LDL-c) were determined enzymatically. ApoAI and apoB levels were measured by immunoturbidometric method. All biochemical tests were performed in serum by COBAS MIRA analyzer and commercial kits (Pars Azmon Co. Iran).

Genetic analysis

Genomic DNA was isolated from blood leukocytes, using a "salting out" procedure (24). A fragment of 428 bp in the apo C III 3'-untranslated region (UTR) of exon 4 containing the polymorphic SstI site, amplified

by Polymerase chain reaction (PCR). The primers (25) used were: F: 5' - GGT GAC CGA TGG CTT CAG TTC CCT GA-3' and R: 5'- CAG AAG GTG GAT AGA GCG CTG GCC T-3'(DNA Technology A/S (Denmark). All reactions were performed in 25 µl reaction volumes containing 100 pmol of each primer, 50 ng genomic DNA, 2.5 µl of 10x reaction buffer, 2 mM MgCl₂, 0.1 mM dNTP and 1 unit Taq DNA polymerase (Roche Diagnostics GmbH, Germany). The PCR conditions were: 1 cycle at 95 °C for 5 min, 35 cycles at 95 °C for 1 min and 1 min at 64 °C, with a final

elongation at 72 °C for 5 min. Five µl of the PCR product were digested at 37 °C for 4 hr with 2.5 units of SstI restriction enzyme (Roche Diagnostics GmbH, Germany) and specific restriction buffer in a final volume of 25 µl. Following digestion, the samples were run on 2% agarose gel and visualized directly over a UV transilluminator. Alleles were defined as S1 and S2 based on the absence or presence of the SstI restriction site, respectively. The presence of the SstI site (S2 allele) resulted in two fragments of 269 and 159 bp (Figures 1 and 2).




Figure 1. Restriction patterns of SstI site. Lanes 2 and 3 are from individuals with S1S2 genotype (The sizes of bands are 428, 269 and 159 bp). Lane 5 is from an individual with S1S1 genotype. Lanes 1 and 4 show the DNA size markers (100 bp and 50 bp , respectively). Agarose 2%, TBE buffer and staining with EB




Figure 2. Restriction patterns of SstI site. Lane 1 is from individual with S1S1 genotype. Lane 2 is from an individual with S2S2 genotype. Lane 3 shows the DNA size markers (100 bp). Agarose 2%, TBE buffer and staining with EB

Statistical analysis

Continuous variable were reported as mean±SEM (standard error of the mean).

Analysis of variance (one-way ANOVA) and student's t-test were used for the comparison of lipid parameters means among the various

SstI Polymorphism of the Apolipoprotein CIII Gene

genotypes. Hardy-Weinberg equilibrium was tested by the X^2 test. The distribution of genotype and allele frequencies between hyperlipidemic subjects and the control group were compared using Pearson's chi-square test. Statistical significance was accepted at $P < 0.05$. Statistical analysis was performed with SPSS10/win statistical software.

Results

Total cholesterol (TC), TG, LDL-C and apo B were significantly ($P < 0.001$) higher in primary hyperlipidemia cases in compare to the control subjects. The hyperlipidemic subjects also had

significant decrease ($P < 0.001$) levels of HDL-c and apoAI compared to the control subjects. The control and patient groups did not differ significantly with respect to age and sex (Table 1).

The distribution of SstI genotypes and alleles frequencies among healthy subjects and hyperlipidemia patients are shown in Table 2. There was significant difference in the genotypes S2 S2 distribution ($P < 0.01$) and rare S2 allele ($P < 0.002$) between the two groups. The distribution of genotypes observed in both groups was in Hardy-Weinberg equilibrium (Table 3).

Table 1. General characteristics and lipid profile (mg/dl) of the study population

Variable	Control (n= 75)	Patient (n= 76)
Age (year)	45.3±1.4	46.1 ± 1.2
Men/women	35/40	34/42
BMI(kg/m ²)	24.7±0.4	26.9±0.4 *
TC	131±5	298±6 *
TG	166±4	430±10 *
LDL-c	68±3	154±5 *
HDL-c	45.4±0.8	35.7±0.8 *
Apo AI	138±2	119±2*
Apo B	48±1.2	114±3*

Data present the mean±SEM; * $P < 0.001$ compared to the control, BMI= Body mass index, TC= Total cholesterol, TG= Triacylglycerol, LDL-c= Low density lipoprotein – cholesterol, HDL-c= High density lipoprotein – cholesterol, ApoAI= Apolipoprotein AI, ApoB = Apolipoprotein B

Table 2. Genetic distribution and allelic frequencies for SstI polymorphism in the subject groups

Genotype	Control n (%) n= 75	Patient n (%) n= 76	P Value
S1S1	56 (74.7)	39 (51.3)	<0.002
S1S2	17 (22.7)	31 (41)	
S2S2	2 (2.7)	6 (8)	
Allele frequency			
S1	86	71.7	< 0.01
S2	14	28.3	

Table 3. Frequency distribution of various genotypes and alleles of Apo CIII SstI polymorphism *

Genotype	Frequency observed genotype (n)	Expected genotype frequency	Allele frequency
S1S1	95	93.8	S1 = 0.79
S1S2	48	50.4	S2 = 0.21
S2S2	8	6.8	
Total (n)	151		

*Test for Hardy-Weinberg equilibrium: Chi-square= 0.34, df= 2, $P > 0.1$

Table 4. Characteristic of patient group according to different genotypes of SstI polymorphism

Variable	S1S1	S1S2	S2S2
N	39	31	6
Age (year)	46±1.7	46.9±1.9	43±5.1
Men/women	22/17	10/21	2/4
BMI (kg/m ²)	26.7±3.7	27.2±0.6	25.9±2.3
TC (mg /dl)	293 ± 9	297 ± 9	309 ± 27
TG (mg /dl)	379 ± 12	468 ± 8	560 ± 38*
LDL-c (mg/dl)	151 ± 6	157 ± 8	153 ± 5
HDL-c (mg/dl)	36.2 ± 0.3	35.4 ± 0.6	34 ± 1.2
LDL-c/HDL-c	4.2± 0.4	4.6± 0.7	4.5± 0.5
Apo AI (mg/dl)	121 ± 2	118 ± 3	117 ± 6
Apo B (mg/dl)	166 ± 8	172 ± 6	163 ± 6

Data present the mean ± SEM; **P*< 0.001 compared to the control, BMI = Body mass index, TC= Total cholesterol, TG= Triglyceride, LDL-c= Low density lipoprotein – cholesterol, HDL-c= High density lipoprotein – cholesterol, Apo-AI= Apolipoprotein AI, ApoB= Apolipoprotein B

Table 5. Characteristic of the control group according to different genotypes of SstI polymorphism

Variable	S1S1	S1S2	S2S2
N	56	17	2
Age (year)	47±1.5	42±3.5	38±4
Men/women	27/29	7/10	1/1
BMI (kg/m ²)	24.2± 0.4	25.75±0.9	25.8± 1.3
TC (mg /dl)	132± 5.1	126 ± 11.5	144 ± 39
TG (mg /dl)	153 ± 3	156 ± 7	160 ± 25
LDL-c (mg/dl)	71 ± 3.8	58.4 ± 4	64.5 ± 19
HDL-c (mg/dl)	44.7 ± 0.8	44.2 ± 2	51 ± 10
Apo AI (mg/dl)	137 ± 2	141 ± 4	137 ± 9
Apo B (mg/dl)	97 ± 4	94 ± 9	105 ± 24

Data present the mean±SEM; **P*< 0.001 compared to the control, BMI= Body mass index, TC= Total cholesterol, TG= Triglyceride, LDL-c= Low density lipoprotein – cholesterol, HDL-c= High density lipoprotein – cholesterol, Apo-AI= Apolipoprotein AI, ApoB= Apolipoprotein B

Table 6. Pearson correlation coefficients between SstI polymorphism and other parameters

	Control group		Patients group	
	r	<i>P</i>	r	<i>p</i>
Age	0.181	0.120	-0.010	0.929
Sex	-0.053	0.650	-0.130	0.265
BMI	-.0.171	0.143	-0.045	0.697
TC	-0.041	0.721	-0.015	0.895
TG	-0.247	0.032*	-0.363	0.001**
LDL-c	0.195	0.093	0.07	0.577
HDL-c	-0.171	0.141	-0.157	0.175
Apo AI	-0.110	0.347	-0.152	0.190
Apo B	0.019	0.872	-0.074	0.528

*Correlation is significant at the 0.01 level (2-tailed); **Correlation is significant at the 0.01 level (2-tailed), BMI= Body mass index, TC= Total cholesterol, TG = Triglyceride, LDL-c = Low density lipoprotein – cholesterol, HDL-c= High density lipoprotein – cholesterol, Apo-AI= Apolipoprotein AI, ApoB= Apolipoprotein B

The lipid and apolipoprotein levels of different genotypes of the HLP and control groups are shown in Tables 4 and 5, respectively. TG was significantly different among various genotypes in the HLP (*P*< 0.001) and control (not

significant) groups. In particular, the concentration of TG was at the highest level in the S2S2 subjects followed by S1S2 and then by S1S1 in the HLP and control groups.

As it has been shown in Tables 4 and 5, no significant differences were observed in TC, LDL-c, HDL-c, apoAI, apoB levels of various genotypes of SstI in both groups.

In the HLP and control groups (Table 6), SstI polymorphism (Presence of S2 allele) correlated significantly with TG ($r=-0.247$ and $r=-0.363$ in the control and patients groups, respectively).

The crude odd ratio (OR) for S1S2 + S2S2 genotypes (in comparison to S1S1 genotype) was found to be 2.8 (95% CI: 1.41-5.56, $P<0.003$), which was highly significant.

Discussion

The prevalence of dyslipidemia in Iranian adults is relatively high. Azizi *et al* (23) reported higher levels of TGs, TC and LDL-c and slightly lower levels of HDL-c in Iranian adults in compare to studies from industrialized countries. In addition to environmental factors, genetic factors play an important role in determining lipid plasma levels (26). Some epidemiological studies have shown associations between polymorphisms in apo AIII-AIV cluster gene and variation in plasma lipids concentration (27 - 29). In addition, many of these studies have been carried out on the SstI polymorphism in the 3' UTR of apo CIII gene (12, 30).

Some studies have showed a large difference in the frequency of the rare S2 allele among races, especially in Caucasians and Non-Caucasians. Although, the frequency of S2 allele in Caucasians has been reported to be 0.16 and 0.09 in hypertriglyceridemic (HTG) and normotriglyceridemic (NTG) individuals (15). The frequencies were higher for different Asian populations (16, 31-35) and 0.28 and 0.14 in the current study.

The observed frequency of S2 allele is higher in Asian populations than in Caucasians. Our data indicated that S2 frequency is higher in Iranian (Middle East) than in Caucasians, and is lower than the S2 frequency reported from South-east Asia region.

We observed that SstI polymorphism was significantly correlated with plasma TG levels.

Our findings were in line with previous studies, which explained a significant SstI polymorphism and TG levels (32, 36).

However, these findings have not been confirmed by other investigators (30, 37). In the present study, S2S2 individuals showed the highest levels of TG followed by S1S2 and S1S1 in HLP ($P<0.001$) and the control groups.

The molecular bases by which the SstI polymorphism can influence the level of TGs are still unknown. Since the SstI polymorphism is located in the non-coding region of exon 4 of the apo CIII gene; it is believed that the S2 allele is in linkage disequilibrium with one or more sequences within or nearby the apo CIII gene, affecting TG concentration. Dammerman *et al* (13) reported that the SstI polymorphism is in linkage disequilibrium with mutations of -625 and -482 in the apo CIII promoter region.

There was no evidence for statistically significant association between SstI polymorphism of the apo CIII gene and TC, HDL-c or LDL-c in the current study. These findings were in agreement with the previous studies (35, 37).

Conclusion

The presence of S2 allele is shown to be associated with high TGs levels in HLP (significant) and normal (not significant) subjects.

Since the current research has been performed in a restricted area and also there are many ethnic groups in Iran, we suggest further studies to be performed on larger populations on different ethnic groups.

Considering the fact that there is a high prevalence of coronary artery disease (CAD) among the Iranian population (38), and also dyslipidemia, including high triglyceride level is a risk factor for CAD, studies investigating the relationship between apo CIII SstI polymorphism and CAD seem necessary to be carried out in Iran.

Acknowledgment

This study was supported by grants from Semnan University of Medical Sciences, Sennan, Iran.

References

1. Groenendijk M, Cantor RM, de Bruin TWA, Dallinga – Thie GM. The apoAI-CIII-AIV gene cluster. *Atherosclerosis* 2001; 157:1-11.
2. Gangabadage CS, Zdunek J, Tessari M, Nilsson S, Olivecrona G, Wijmenga SS. Structure and dynamics of human apolipoprotein CIII. *J Biol Chem* 2008; 283:17416-17427.
3. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. *Arterioscler Thromb Vasc Biol* 1999; 19:472-484.
4. Buzza M, Fripp Y, Mitchell RJ. Apolipoprotein AI and CIII gene polymorphisms and their association with lipid levels in Italian, Greek and Anglo-Irish populations of Australia. *Ann Hum Biol* 2001; 28:481-490.
5. Voshol PJ, Rensen PC, van Dijk KW, Romijn JA, Havekes LM. Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models. *Biochim Biophys Acta* 2009; 1791:479-485.
6. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. *Science* 1990; 249:790-793.
7. Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K, Yoshida M. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. *Circulation* 2008; 118:731-742.
8. Karathanasis SK, Oettgen P, Haddad IA, Antonarakis SE. Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4). *Proc Natl Acad Sci U S A* 1986; 83:8457-8461.
9. Garasto S, Rose G, Derango F, Berardelli M, Corsonello A, Feraco E, *et al*. The study of apoA1, apoC3 and apoA4 variability in healthy ageing people reveals another paradox in the oldest old subjects. *Ann Hum Genet* 2003; 67:54-62.
10. Xu CF, Talmud P, Schuster H, Houlston R, Miller G, Humphries S. Association between genetic variation at the apo AI-CIII-AIV gene cluster and familial combined hyperlipidaemia. *Clin Genet* 1994; 46:385-397.
11. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. *J Clin Invest* 1995; 96:2601-2605.
12. Surguchov AP, Page GP, Smith L, Patsch W, Boerwinkle E. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. *Arterioscler Thromb Vasc Biol* 1996; 16:941-947.
13. Dammerman M, Sandkuijl LA, Halas JL, Chung W, Breslow JL. Anapolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. *Proc Natl Acad Sci USA* 1993; 90:4562-4566.
14. Brown S, Ordovás JM, Campos H. Interaction between the apoC3 gene promoter polymorphisms, saturated fat intake and plasma lipoproteins. *Atherosclerosis* 2003; 170:307-313.
15. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. *Atherosclerosis* 1993; 00157-169.
16. Ko YL, Ko YS, Wu SM, Teng MS, Chen FR, Hsu TS, *et al*. Interaction between obesity and genetic polymorphisms in the apolipoprotein CIII gene and lipoprotein lipase gene on the risk of hypertriglyceridemia in Chinese. *Hum Genet* 1997; 100:327-333.
17. Hoffer MJ, Sijbrands EJ, De Man, FH, Havekes LM, Smelt AH, Frants RR. Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. *Eur J Clin Invest* 1998; 28:807-812.
18. Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, North JD, *et al*. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. *Atherosclerosis* 1991; 87:239-247.
19. Dallinga-Thie GM, Bu XD, Van Linde-Sibenius Trip M, Rotter JI, Lusi AJ, de Bruin TW. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. *J Lipid Res* 1996; 37:136-147.
20. Marcil M, Boucher B, Gagné E, Davignon J, Hayden M, Genest JJ. Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. *J Lipid Res* 1996; 37:309-319.
21. Price WH, Morris SW, Kitchin AH, Wenham PR, Burgon PR, Donald PM. DNA restriction fragment length polymorphisms as markers of familial coronary heart disease. *Lancet* 1989; 24:1407-14011.
22. Thu NN, Tuyet Mai TT, Ohmori R, Kuroki M, Van Chuyen N, Kim Hung NT, *et al*. Plasma triglyceride and HDL-Cholesterol concentrations in vietnamese girls are affected by lipoprotein lipase, but not apolipoprotein CIII polymorphism. *J Nutr* 2006; 136:1488-1492.
23. Azizi F, Rahmani M, Ghanbarian A, Emami H, Salehi P, Mirmiran P, Sarbazi N. Serum lipid levels in an Iranian adult population: Tehran lipid and glucose study. *Eur J Epidemiol* 2003; 18:311-319.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988; 11:16:1215.

SstI Polymorphism of the Apolipoprotein CIII Gene

25. Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, Wilson PW, *et al.* Association of the Sst-I polymorphism at the apoC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. *Atherosclerosis* 2001; 158:173-181.
26. Ordovas JM, Lopez-Miranda J, Mata P, Perez-Jimenez F, Lichtenstein AH, Schaefer EJ. Gene-diet interaction in determining plasma lipid response to dietary intervention. *Atherosclerosis* 1995; 118:S11-27.
27. Dallinga-Thie GM, Van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu X, Lusa AJ, *et al.* Complex genetic contribution of the apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. *J Clin Invest* 1997; 1:953-961.
28. Xu CF, Angelico F, Del Ben M, Humphries S. Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo AI levels in boys and girls. *Genet Epidemiol* 1993; 10:113-122.
29. Ordovas JM, Civeira F, Genest J Jr, Craig S, Robbins AH, Meade T, *et al.* Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. *Atherosclerosis* 1991; 87:75-86.
30. Dallongeville J, Meirhaeghe A, Cottel D, Fruchart JC, Amouye IP, Helbecque N. Gender related association between genetic variations of apoC-III gene and lipid and lipoprotein variables in northern France. *Atherosclerosis* 2000; 150:149-157.
31. Zeng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. *Hum Genet* 1995; 95:371-375.
32. Huang MC, Wang TN, Liu YL, Pa TH, Tu HP, Huang YC, *et al.* Effect of SstI polymorphism of the apolipoprotein CIII gene and environmental factors on risks of hypertriglyceridemia in Taiwan aborigines. *Circ J* 2006; 70:1030-1036.
33. Hong SH, Park WH, Lee CC, Song JH, Kim JQ. Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects. *Clin Chem* 1997; 43:13-17.
34. Taş S. Strong association of a single nucleotide substitution in the 3'-untranslated region of the apolipoprotein-CIII gene with common hypertriglyceridemia in Arabs. *Clin Chem* 1989; 35:256-259.
35. Chhabra S, Narang R, Krishnan LR, Vasisht S, Agarwal DP, Srivastava LM, *et al.* Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. *BMC Genet* 2002; 6:3:9.
36. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, *et al.* Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. *J Atheroscler Thromb* 2005; 12:240-250.
37. Kee F, Amouyel P, Fumeron F, Arveiler D, Cambou JP, Evans A, *et al.* Lack of association between genetic variations of apo A-I-C-III-A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study. *Atherosclerosis* 1999; 145:187-195.
38. Sarraf-Zadegan N, Sayed-Tabatabaei FA, Bashardoost N, Maleki A, Totonchi M, Habibi HR, *et al.* The prevalence of coronary artery disease in an urban population in Isfahan, Iran. *Acta Cardiol* 1999; 54:257-263.